Please ensure Javascript is enabled for purposes of website accessibility

Coronavirus Impacts Lead Johnson & Johnson to Slash Its 2020 Expectations

By Cory Renauer – Updated Apr 14, 2020 at 5:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The upbeat earnings guidance the company issued in January no longer applies in a pandemic-ravaged economy.

Johnson & Johnson (JNJ -0.71%) kicked off earnings season for the healthcare sector on Tuesday, and based on what its management had to say, it looks like investors should brace themselves for more disappointment ahead. The positive earnings guidance it issued just three months ago has been totally upended by the COVID-19 pandemic.  

Unprecedented change 

In 2019, Johnson & Johnson earned an adjusted $8.68 per share and in January, the company told investors to expect between 3.1% and 4.8% more in 2020. While first-quarter results were better than expected for J&J's pharmaceutical and consumer goods segments, the company's outlook for 2020 is markedly worse than it was.

Doctor in personal protective equipment.

Image source: Getty Images.

Rather than a modest gain for the year, Johnson & Johnson now expects to earn 11.2% less in 2020 at the midpoint of its new guidance range. After factoring in the expected impact of the coronavirus pandemic on the company's business, management cut its forecast for adjusted earnings to between $7.50 and $7.90 per share.

Hang on

Although Johnson & Johnson's outlook turned negative, it did beat expectations on the top and bottom lines in the first three months of 2020. Adjusted earnings of $2.30 per share were 15% higher than analysts' consensus estimate. And the $20.7 billion in revenue beat analysts' expectations by 6%.  

The company signaled confidence in its long-term future with its 58th consecutive annual dividend bump. In June, shareholders will receive a quarterly payout of $1.01 per share, 6.3% higher than its previous dividend.

Cory Renauer owns shares of Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
$163.36 (-0.71%) $-1.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.